![Luminus Biosciences](https://austinbio.tech/wp-content/uploads/2023/02/favicon-neu.png)
Preclinical Studies
Preclinical Study Results of ABC‑1103
Austin Biosciences has completed several key preclinical studies, including a maximum tolerated dose (MTD) study, a pharmacokinetics study, and biological activities in a breast tumor xenograft model, and in a pancreatic tumor xenograft model.
Results show ABC-1103 vs. Taxotere® has significantly greater anti-tumor activity with potentially reduced toxicity.
![](https://austinbio.tech/wp-content/uploads/2023/02/iStock-497119410-scaled.jpg)